Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Circulation|August 28, 2022
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial InfarctionSunil V Rao, Bodo Kirsch, Deepak L Bhatt, et al.
Stroke|June 11, 2020
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS TrialRobert Mikulík, Jens Eckstein, Lesly A Pearce, et al.
NPJ Digital Medicine|June 28, 2022
Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP)Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, et al.
JAMA Cardiology|May 30, 2019
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary SyndromesThomas J Povsic, E Magnus Ohman, Matthew T Roe, et al.
JACC. Advances|November 21, 2024
Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation: The PEARL-AF StudyShelby D Reed, Josephine L Harrington, Daniel P Morin, et al.
Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.
Stroke|January 4, 2024
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct OutcomesEric E Smith, Ashkan Shoamanesh, Lizhen Xu, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 22, 2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapySebastian F Ameriso, Pierre Amarenco, Lesly A Pearce, et al.
The New England Journal of Medicine|November 7, 2012
Effects of dalcetrapib in patients with a recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Markus Abt, et al.
Stroke|August 13, 2019
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid AtherosclerosisGeorge Ntaios, Balakumar Swaminathan, Scott D Berkowitz, et al.
Pageof 5